GLP-1 receptor

The GLP-1 receptor is the docking point that every drug in this category is built to hit. Glucagon-like peptide-1 is a hormone your small intestine releases within minutes of eating. It tells the pancreas to release insulin when glucose is high, tells it to hold back glucagon, slows the stomach’s emptying, and — the part that matters most for weight — signals satiety in the brain. Drug labels describe GLP-1 as a physiological regulator of appetite and calorie intake, with receptors present in several brain regions involved in appetite regulation.

Your own GLP-1 is almost useless as a medicine because it disappears so fast. The Saxenda label puts native GLP-1’s half-life at 1.5 to 2 minutes, chewed up by enzymes called DPP-4 and neutral endopeptidases. Every GLP-1 drug is essentially a solution to that problem. Liraglutide shares 97% of its amino acid sequence with human GLP-1 and survives about 13 hours. Semaglutide shares 94% and lasts about a week. The receptor being activated is the same one; the engineering is all about persistence.

That is why side effects and benefits travel together. Slowed stomach emptying is why food stays satisfying longer, and it is also why nausea and constipation are the most common complaints. Glucose-dependent insulin release is why hypoglycemia is uncommon on a GLP-1 alone but becomes a real risk when one is added to insulin or a sulfonylurea.

The usual confusion is thinking the receptor lives only in the gut. It does not — GLP-1 receptors sit in the brainstem and hypothalamus, in the pancreas, and in blood vessel walls, which is part of why these drugs show effects on cardiovascular events and kidney function that weight loss alone does not fully explain.

Worth raising with a clinician: whether you are on any other medication that lowers blood sugar, since that combination changes the safety picture; and whether a drug that also hits a second receptor, like tirzepatide, is a better fit. Our incretin effect explainer and onset-of-action guide go further.